46 points as of 0157GMT Reporting by Jungyoun Park editing by Jonathan Hopfner

) World No. 3 Andy Murray has withdrawn from the Masters 1000 Event in Shanghai next week as he attempts to recover from a wrist injury.Murray has been one of the most consistent tennis players on the tour this year The Scot won the Masters 1000 events in Miami and Montreal. Murray also reached the Semifinals at Wimbledon for the first time this year, where he lost out in four tight sets to the American Andy Roddick.Last year the prestigious Masters Cup was held in Shanghai, and on that occasion Murray managed to reach the Semifinals, beating Roger Federer along the way, before eventually falling to Russia's Nikolay Davydenko.Murray previously had wrist problems back in 2007 and that forced him to miss six months of action, but following his shocking fourth round defeat at this year's U.S. Open to Marin Cilic Murray said he is prepared to rest for as long as possible in order to get his wrist back to full strength.If you are a betting person then you would do well to back Murray to win a Grand Slam next year..

SEOUL, Jan 28 (Reuters) - The Korea Exchange temporarilysuspended programme buying orders on the main Korea CompositeStock Price Indexon Wednesday due to volatile futuresprices. The suspension, the second this year, was scheduled for fiveminutes from 0154 GMT. The index was up 4.49 percent at 1,142.46 points as of 0157GMT (Reporting by Jungyoun Park; editing by Jonathan Hopfner). DUBLIN, Ireland(Business Wire)Research and Markets( http://) hasannounced the addition of the "The Pharmaceutical Market: Singapore" report totheir offering. Singapore is ranked among one of the most open economies in the world, andremains a popular destination for companies using the country as a trading basefor the South East Asian region. Incentives such as low corporate tax rates andstrong intellectual property laws enabled Singapore to secure S$932.4 million(US$618.7 million) in commitments to invest in the biomedical manufacturingindustry (pharmaceutical and medical devices) in 2007 alone. These investmentshave grown strongly each year but recent economic events could result innegative growth in the future.

As strong as Singapore's economy is in Asia, let alone the world, the factremains that it is an export driven one, and the slowdown has already taken itstoll on the manufacturing sector. This will inevitably result in a furthercontraction of growth in pharmaceutical output in the short term at least. More recent data show a sharp decline in production, with the EconomicDevelopment Board (EDB) reporting a 30.6 decline in biomedical output (thisincludes both pharmaceuticals and medical devices) in October 2008, compared tothe year before. More worryingly for these domestic manufacturers, it was thebiomedical sector that led the decline in manufacturing during the period inquestion. Business opportunities in Asian pharmaceutical markets are very different from afew years ago.